Sanjay Kaul

TL;DR: The current status of this controversy is reviewed, the additional evidence needed for its resolution is described, and recommendations for regulatory reform and 3 specific recommendations to encourage evidence-based patient management are offered.

TL;DR: In this paper, the authors review the current status of this controversy, describe the additional evidence needed for its resolution, and offer recommendations for regulatory reform and 3 specific recommendations to encourage evidence-based patient management: 1) an emphasis on medical therapies with proven longterm benefit; 2) the use of kinetic modeling to estimate long-term outcomes of therapies based on the available near-term data.

TL;DR: The solutions offered in this statement represent ways to translate the totality of published reports into enhanced hyperlipidemia guidelines to better combat the devastating impact of hyper Lipidemia on cardiovascular health.

TL;DR: Magnesium produced a significant reduction in acute stent thrombus formation that was equivalent in magnitude to that produced by clinically relevant doses of tirofiban and eptifibatide, and its potential use in percutaneous coronary intervention requires further study.

TL;DR: The results of these trials yield a favorable benefit-risk balance for these therapies in mitigating CV risk in patients with type 2 diabetes, and more research is needed to elucidate the underlying mechanisms and confirm whether the CV benefits are a class effect or whether the benefits persist in patients without established CV disease or are evident even in patients Without diabetes.